Atomoxetine for Freezing of Gait in Parkinson's Disease
Status:
Completed
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
Subjects are being asked to participate in this study to determine the safety and
effectiveness of a drug called atomoxetine in the treatment of freezing of gait for
Parkinson's Disease patients. Atomoxetine (ATM) is an approved drug currently on the market
for the treatment of attention deficit. It works to increase the amount of norepinephrine (a
chemical in the brain that helps keep us awake and alert) in our brain. ATM has not been
approved by the Food and Drug Administration (FDA) to be used in the treatment of PD, but has
been found to be well tolerated in this patient population.